DoW Vision, Clinical Trial Award
Per-recipient award not stated for unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "additional information on eligibility", closing Nov 12, 2026.
In one sentence
DoW Vision, Clinical Trial Award does not state a per-recipient award amount, open to unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "additional information on eligibility", closing Nov 12, 2026.
- Program pool (total)
- $2,600,000Total across all awards in this programme. Not an amount any single applicant can receive.
- Award ceiling (per project)
- Not confirmed
- Award floor
- Not confirmed
- Typical award
- Not confirmed
- Deadline
- Nov 12, 2026
- Deadline type
- Fixed date
- Opens
- May 5, 2026
- Status
- Open
- Eligible entities
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- Geography
- Not stated
- Matching funds
- No
- Disbursement
- Not confirmed
- Application effort
- Not confirmed
- Use of funds
- Clinical trials · Service-connected eye injury and visual dysfunction treatment or management
- Currency
- USD
How much money is available?
Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.
Who can apply?
Not confirmed
Source field: applicant size limitNot confirmed
We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.When does it close?
IND/IDE or equivalent must be submitted by the CTA application submission deadline; documentation of active/safe to proceed status by March 1, 2027.
What can the money be used for?
2 categorysThe source’s own spending categories, and what is not parsed.
These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.
How hard is the application?
1 fieldEffort, match requirement and reimbursement, as the source stated them.
- Application effort
- Not confirmed
- Disbursement
- Not confirmed
- Matching funds
- No
Common questions
5 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
- How much funding is available in total?
- $2,600,000 across the whole programme. This is the total the funder has allocated, not an amount any single applicant can receive.
- When is the application deadline?
- Nov 12, 2026. IND/IDE or equivalent must be submitted by the CTA application submission deadline; documentation of active/safe to proceed status by March 1, 2027.
- Who is eligible to apply?
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility".
- What can the funding be used for?
- Clinical trials, Service-connected eye injury and visual dysfunction treatment or management, as classified by the source.
- Is matching funding required?
- No. The source states that no matching funds are required.
AI summary of the source text
Optional. Every core field on this record is already above, free and complete.
AI summary of the source text
Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.
Included with Studio
Sign inThe official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.